{"pmid":32332039,"title":"Renin-angiotensin-aldosterone system inhibitors and COVID-19.","text":["Renin-angiotensin-aldosterone system inhibitors and COVID-19.","CMAJ","Quinn, Kieran L","Fralick, Michael","Zipursky, Jonathan S","Stall, Nathan M","32332039"],"journal":"CMAJ","authors":["Quinn, Kieran L","Fralick, Michael","Zipursky, Jonathan S","Stall, Nathan M"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32332039","week":"202017|Apr 20 - Apr 26","doi":"10.1503/cmaj.200619","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"e_drugs":["Aldosterone"],"_version_":1665071049629237249,"score":8.518259,"similar":[{"pmid":32227760,"pmcid":"PMC7121452","title":"Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.","text":["Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.","N Engl J Med","Vaduganathan, Muthiah","Vardeny, Orly","Michel, Thomas","McMurray, John J V","Pfeffer, Marc A","Solomon, Scott D","32227760"],"journal":"N Engl J Med","authors":["Vaduganathan, Muthiah","Vardeny, Orly","Michel, Thomas","McMurray, John J V","Pfeffer, Marc A","Solomon, Scott D"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32227760","week":"202014|Mar 30 - Apr 05","doi":"10.1056/NEJMsr2005760","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"e_drugs":["Aldosterone"],"_version_":1664640912704143360,"score":176.15282},{"pmid":32274522,"title":"Inhibitors of the renin-angiotensin system and SARS-CoV-2 infection.","text":["Inhibitors of the renin-angiotensin system and SARS-CoV-2 infection.","Herz","Kessler, Thorsten","Schunkert, Heribert","32274522"],"journal":"Herz","authors":["Kessler, Thorsten","Schunkert, Heribert"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32274522","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s00059-020-04920-4","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664637190114639873,"score":118.20374},{"pmid":32286678,"title":"Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19.","text":["Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19.","Coronavirus disease 2019 (COVID-19), which initially began in China, has spread to other countries of Asia, Europe, America, Africa and Oceania, with the number of confirmed cases and suspected cases increasing each day. According to recently published research, it was found that the majority of the severe cases were elderly, and many of them had at least one chronic disease, especially cardiovascular diseases. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) are the most widely used drugs for cardiovascular diseases. The clinical effect of ACEIs/ARBs on patients with COVID-19 is still uncertain. This paper describes their potential role in the pathogenesis of COVID-19, which may provide useful in the advice of cardiologists and physicians.","Cardiol J","Huang, Ziyin","Jiang, Yufeng","Chen, Jingjing","Zhou, Yafeng","32286678"],"abstract":["Coronavirus disease 2019 (COVID-19), which initially began in China, has spread to other countries of Asia, Europe, America, Africa and Oceania, with the number of confirmed cases and suspected cases increasing each day. According to recently published research, it was found that the majority of the severe cases were elderly, and many of them had at least one chronic disease, especially cardiovascular diseases. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) are the most widely used drugs for cardiovascular diseases. The clinical effect of ACEIs/ARBs on patients with COVID-19 is still uncertain. This paper describes their potential role in the pathogenesis of COVID-19, which may provide useful in the advice of cardiologists and physicians."],"journal":"Cardiol J","authors":["Huang, Ziyin","Jiang, Yufeng","Chen, Jingjing","Zhou, Yafeng"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32286678","week":"202016|Apr 13 - Apr 19","doi":"10.5603/CJ.a2020.0056","keywords":["2019-ncov","covid-19","angiotensin-converting enzyme inhibitors","renin-angiotensin system"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["China","America"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664636391618772992,"score":114.18553},{"pmid":32281055,"title":"Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19.","text":["Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19.","There is ongoing debate on the safety of renin-angiotensin system (RAS) inhibitors in COVID-19. Recently published studies highlight a potential relationship between cardiovascular disease (CVD) and COVID-19. This article aims to summarize the evidence on the use of RAS inhibitors in CVD patients with COVID-19, focusing on safety issues of the RAS inhibitors and their relationship with COVID-19.","Am J Cardiovasc Drugs","Kow, Chia Siang","Zaidi, Syed Tabish Razi","Hasan, Syed Shahzad","32281055"],"abstract":["There is ongoing debate on the safety of renin-angiotensin system (RAS) inhibitors in COVID-19. Recently published studies highlight a potential relationship between cardiovascular disease (CVD) and COVID-19. This article aims to summarize the evidence on the use of RAS inhibitors in CVD patients with COVID-19, focusing on safety issues of the RAS inhibitors and their relationship with COVID-19."],"journal":"Am J Cardiovasc Drugs","authors":["Kow, Chia Siang","Zaidi, Syed Tabish Razi","Hasan, Syed Shahzad"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32281055","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s40256-020-00406-0","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664636704031506434,"score":114.18553},{"pmid":32292865,"pmcid":"PMC7118533","title":"COVID-19 and the Renin-Angiotensin System.","text":["COVID-19 and the Renin-Angiotensin System.","Kidney Int Rep","Malha, Line","Mueller, Franco B","Pecker, Mark S","Mann, Samuel J","August, Phyllis","Feig, Peter U","32292865"],"journal":"Kidney Int Rep","authors":["Malha, Line","Mueller, Franco B","Pecker, Mark S","Mann, Samuel J","August, Phyllis","Feig, Peter U"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292865","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.ekir.2020.03.024","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664636192535085056,"score":108.62963}]}